首页GEDSF • OTCMKTS
add
Gedeon Richter ADR
市场资讯
财务信息
损益表
收入
净收入
| (HUF) | 2024年9月info | 年同比变化 |
|---|---|---|
收入 | 2167.30亿 | 14.95% |
经营支出 | 946.86亿 | 10.59% |
净收入 | 370.60亿 | -32.07% |
净利润率 | 17.10 | -40.89% |
每股收益 | — | — |
息税折旧摊销前利润 | 763.89亿 | 23.89% |
有效税率 | 19.13% | — |
资产负债表
总资产
负债总额
| (HUF) | 2024年9月info | 年同比变化 |
|---|---|---|
现金及短期投资 | 749.87亿 | -29.24% |
总资产 | 1.49万亿 | 9.53% |
负债总额 | 2588.34亿 | -1.37% |
权益总额 | 1.23万亿 | — |
发行在外的股份 | 1.83亿 | — |
市净率 | 0.00 | — |
资产回报率 | 10.29% | — |
资本回报率 | 11.59% | — |
现金流
现金净变动
| (HUF) | 2024年9月info | 年同比变化 |
|---|---|---|
净收入 | 370.60亿 | -32.07% |
来自运营的现金 | 675.52亿 | 56.30% |
投资现金 | -136.88亿 | 54.12% |
融资现金 | -366.96亿 | -409.23% |
现金净变动 | 171.18亿 | -34.71% |
自由现金流 | 131.87亿 | 1,594.12% |
简介
Gedeon Richter Plc. is a European multinational pharmaceutical and biotechnology company headquartered in Budapest. It is the largest pharmaceutical company in Central and Eastern Europe, with an expanding direct presence in Western Europe, China, Northern America and Latin America. Richter has the largest R&D unit in Central and Eastern Europe and operations in over 100 countries.
Gedeon Richter Plc. has a primary listing on the Budapest Stock Exchange and is a constituent of the BUX Index. It had a market capitalisation of approximately $6.6 billion as of 2018, the third largest of companies with a primary listing on the Budapest Stock Exchange. It has secondary listings on the Luxembourg Stock Exchange.
Richter sells products for the central nervous system, women's health and cardiovascular therapeutic areas among others. The company is also active in biosimilar product development. The company was established in Budapest by Gedeon Richter, a pharmacist, in 1901. Wikipedia
CEO
成立时间
1901
员工数量
11,603
